- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Sean McGowan on What’s in Store for Biosimilars in 2021 and Beyond
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, discusses how 2020 has affected biosimilar development and his predictions for the industry going forward.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, recently appeared during a series of interviews on MJH Life Sciences™’ Medical World News about the challenges of bringing a biosimilar to market, how to ensure biosimilar competition in the future, and what to keep an eye on as the market grows over time. Today, we are bringing you the first part of that discussion, which focuses on McGowan’s thoughts on how 2020 has shaped biosimilar progress and his main predictions for the future of the biosimilars industry.
To watch the full first part of this interview, click here.
To watch part 2 of this interview, click here.
To watch part 3 of this interview, click here.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
